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Worldwide millions of patients are treated with therapeutic monoclonal antibodies.
These biological therapeutics can be immunogenic, resulting in anti drug antibody (ADA) formation which leads to loss of response. Fully human biologics such as the anti-TNF antibody adalimumab are considered to be weakly immunogenic, but we recently detected anti-drug antibodies (ADA) in more then half of the treated rheumatoid arthritis (RA) patients within 28 weeks of treatment. Here we unravelled the mechanism by which ADA lead to loss of response by investigating the full specificity of the repertoire of antiadalimumab antibodies. The specificity of the repertoire of anti-adalimumab antibodies in a cohort of 50 ADA-positive RA patients was elucidated. Therefore, inhibition experiments using TNF and patient derived anti-adalimumab monoclonal antibodies were performed.
The antibody response against adalimumab is highly restricted: Fab fragments of a single, monoclonal antibody specific for the idiotype of adalimumab inhibited 98.65% (25 th -75 th percentiles: 98.25-99.90) of the total anti-adalimumab reactivity in sera of 50 different ADA-positive RA patients. Furthermore, we found that the anti-adalimumab response is confined to the TNF binding region of adalimumab, thereby neutralizing its therapeutic efficacy. In line with this restricted specificity, we observed small immune complexes in the circulation of ADA-forming patients. The humoral immune response against adalimumab is highly restricted and limited to the idiotype of the therapeutic antibody. All antibodies result in functional neutralization of the drug, thereby providing a mechanism in which ADA formation leads to clinical non-response.
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IntroductIon
The use of therapeutic monoclonal antibodies has revolutionized the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. However, long term treatment with therapeutic monoclonal antibodies can induce anti drug antibody (ADA) formation that is associated with lower drug levels and clinical non-response. [1] [2] [3] [4] The mechanism in which the formation ADA hampers clinical response is still unknown. We hypothesize two possible mechanisms. First, administration of a drug to patients producing ADA leads to the formation of immune complexes which might result in accelerating clearance of the drug. Second, neutralizing ADAs might block the binding of the drug to its target. In this study we unravel the mechanism by which the ADA response against adalimumab leads to clinical non-response. We do so by studying the diversity of epitopes involved in the antibody response against adalimumab and to which extent these are located on the antigen binding part of adalimumab, thus blocking binding to TNF.
MAterIAls And Methods

Patients
For the isolation of B-cells, citrated blood was collected from an adalimumab (Abbot, Illanois, USA) treated patient with Ankylosing Spondylitis and known high titers of ADA.
This patient reponded very well at the strat of adalimumab treatment but shows increased disease activity after two months. After a total of five months of treatment adalimumab therapy was discontinued. The patient did not suffer from any adverse events. For this study, blood, containing 2690 AE of ADA and no adalimumab, was withdrawn two weeks after ceasing therapy. The study was approved by the local ethics committee. 10 For the inhibition studies, some sera of patients from the observational cohort of adalimumab-treated ADA RA patients were used, but mainly adalimumab treated patients send in to our diagnostics department. 3;9 Of these patients send in to our diagnostic department no further clinical data are available.
Bridging ELISA for the measurement of ADA Measurements of ADA in the bridging ELISA were essentially carried out as described before. 18 Maxisorp ELISA plates (NUNC) were coated overnight with 100 µl 0.5 µg/ml adalimumab in PBS. After washing 5 times with PBS-Tween (PT), plates were incubated with samples of interest (diluted appropriately in HPE, Sanquin, Amsterdam, the Netherlands).
Subsequently the plates were washed and incubated for 1 hour with biotinylated adalimumab (5 ng/ml in HPE). After washing streptavidin-poly-HRP (Sanquin) (1/10,000
in High Performance ELISA buffer (HPE)) was added for 20 minutes for detection. After washing with PT the ELISA was developed with 100 µg/ml tetramethylbenzidine (TMB) in CD40L-expressing EL4-B5 cells. 19 After 14 days, supernatants were tested for specific antiadalimumab production in a bridging ELISA.
Production of recombinant human antibodies RNA was isolated from wells containing antigen specific B-cells using Trizol (Peqlab, Erlangen, Germany). cDNA synthesis and RACE PCR were performed using the Clontech SMART cDNA synthesis kit (Clontch, Mountain view, USA, cat 634914). RACE PCR products for VL and VH were treated with T4 DNA polymerase and cloned into pcDNA3.3
(Invitrogen) expression vectors containing ligation-independent cloning sites followed by the constant domains of the human Kappa and human IgG1 allotype f genes, essentially as described before. 20 Expression vectors were used for transient transfection of HEK293F cells with 293fectin and OptiMEM (Invitrogen), using the Freestyle HEK293F expression system (Invitrogen) according to the instructions supplied by the manufacturer.
Competition ELISA with recombinant monoclonal antibodies Maxisorp ELISA plates were coated o/n with 0.5 µg/ml adalimumab in PBS. The binding of biotinylated anti-adalimumab 1.1 and anti-adalimumab 1.2 was analysed after preincubation of the coat with increasing amounts of unlabeled anti-adalimumab 1.1 and anti-adalimumab 1.2. All incubations were performed in HPE. After washing streptavidinpoly-HRP (Sanquin) (1:10.000 in HPE) was added for twenty minutes, after which the ELISA was developed using TMB as described above.
Antigen binding test, inhibited by human monoclonal antibodies or rTNF F(ab')2 and Fab fragments were generated as described before. 15 The antigen-binding test (ABT) was described before. 15 22 were seeded in a 96 wells plate in IMDM containing 5% FCS (Bodinco), 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µM 2-ME, 20 µg/ml human apo-transferrin (Sigma-Aldrich). After 24 hours of incubation the samples containing TNF, adalimumab and Fab fragments of monoclonal antibody were added. Supernatants were harvested after 24 hrs incubation and tested for IL-8 concentration by ELISA. 23 Sucrose gradients Sera were analysed by isokinetic sucrose gradient centrifugation. 24 Sucrose gradients (5-32.9%, w/v, sucrose; Merck) were prepared in PBS, pH 7.4 containing 5 mM EDTA and 0.1% Tween (PET). 100µl serum or 500 AE of patient ADA was diluted in 200 µl PET and layered onto the sucrose gradient. The gradients were centrifuged in a Beckman swing out rotor type SW 41 at 36.000 rpm for 16 hours at 20°C. Fractions of 500 µl were collected and ADA levels were detected using the ABT and the PIA. IgG levels were determined by ELISA. Briefly, Maxisorp ELISA plates were coated o/n with 1µg/ml Sheep-anti-human IgG (SH16-1) (Sanquin) in PBS. For detection 1 µg/ml biotinylated monoclonal anti human IgG (MH16-1) (Sanquin) in HPE was used. Afterwards MH16-1 binding was detected using poly-HRP and TMB as described above.
results
Isolation and characterization of anti-adalimumab producing B-cells
In order to investigate the mechanism by which ADA lead to clinical non-response we first wanted to study the number of epitopes involved in the immune response against adalimumab. Therefore we obtained adalimumab-specific monoclonal antibodies.
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Chapter 5 3 ). In the absence of adalimumab, the recombinant monoclonal antibody had no agonistic or antagonistic effect on the ECRF-24 cells (see figure S1 ).
All tested anti-adalimumab positive patient sera were able to neutralize adalimumab activity in the TNF bioassay, showing that in all patients at least part of the ADA are neutralizing. To investigate which fraction of the polyclonal response is neutralizing we performed an ABT in which radiolabeled adalimumab F(ab')2 was pre-incubated with increasing amounts of TNF. The presence of ADA-drug complexes in serum may lead to false-positive results due to cross-linking of radiolabeled adalimumab F(ab')2 to complexderived adalimumab by the homotrimeric TNF (for cartoon see figure S2 ). To circumvent this, we fractionated sera of six patients with high anti-adalimumab levels on sucrose gradients to separate the free monomeric ADA from ADA-drug complexes as we described before. 15 TNF dose-dependently inhibited the binding to radiolabeled adalimumab F(ab')2 of anti-adalimumab, derived from six patient sera as well as monoclonal anti-Chapter 5 adalimumab 1.2 ( figure 4 ). These data clearly show that the humoral immune response against adalimumab in all tested patients is restricted to the TNF binding region of adalimumab.
The restricted immune response against adalimumab leads to small immune complexes An antibody response against a very restricted immunogenic region, as we describe here for adalimumab, is expected to result in formation of small immune complexes which might not be efficiently cleared from the circulation. We recently described a new assay which is able to measure anti drug antibodies in complex with adalimumab, enabling us to analyze the size of adalimumab/anti-adalimumab complexes in sera of patients. 15 To this end we fractionated ADA positive patient sera with difference levels of ADA and adalimumab, collected just prior to the next administration of adalimumab, on sucrose gradients and measured which fractions contained adalimumab/anti-adalimumab In light of these new data showing that all antibodies are neutralizing, it might seem contradictory that only part of the ADA producing patients lose responsiveness. However, we hypothesise that clinical response is dependent on the maginitude of the immune response. Low ADA levels might not alter clinical response of patients since here only al small portion of the adalimumab is neutralized. Therefore these patients would still have sufficient drug levels to respond to treatment. Only in patients which produce high levels of ADA, the majority or all adalimumab is neutralized leading to non response to treatment.
Yet another mechanism by which ADA could interfere with effectiveness of the therapeutic monoclonal antibody is in case ADA bear an "internal image" of the antigen.
Previous studies by others have shown that an antigen bound by a particular antigen combining region (idiotype) of an antibody may be functionally mimicked by a secondary anti-idiotype antibody that binds to the same region of that idiotype. For therapeutic antibodies this holds the risk that anti-idiotype antibodies against the therapeutic antibody may resemble the target protein and in case of adalimumab therefore react with the TNFreceptor. This could be detrimental for the effectiveness of the therapeutic monoclonal antibody. However, the anti-idiotype monoclonal antibodies against adalimumab that Chapter 5 we isolated and subsequently cloned showed no effect at all on the TNF-receptor as we tested in a TNF bio-assay (figure S1). Reactivity of anti-idiotype antibodies against adalimumab with the TNF receptor can only be expected if adalimumab binds to the exact same region on TNF as the TNF receptor does. as serum sickness and SLE. A recently published paper shows an increased incidence of severe venous and arterial tromboembolic events in patients that produce ADA against adalimumab. 25 It would be interesting to investigate whether the presence of these immune complexes leads to serious side effects. In this light, our previous finding that most patients make antibodies against adalimumab, even at levels that do not preclude full neutralization, gain new importance. 15 It is likely that in most patients small circulating immune complexes are chronically induced.
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